Article

Being Told You'll Be Fine After Cancer

Author(s):

Perhaps by saying I’ll be fine, you are really saying that you don’t have to think of me in any other way.

It’s interesting how others react to those of us with a cancer diagnosis. There really are not any guidebooks for people about what to say or do and what not to say or do. Most just follow their heart. Or not.

I have witnessed a wide range of reactions. There were those who were very uncomfortable to see what I was going through. Not being able to express their concern, they simply didn’t say or even do anything. Some were afraid they could “catch” it. Witnessing me - a healthy, vibrant woman who “got cancer” and, overnight, became, “a sick” human being, couldn’t it happen to them?

However, the most pronounced reaction to my treatment and certainly when I was “finished” with treatment was the statement I heard repeatedly — “You’ll be fine.” It was kind of like I was over a bad cold. Perhaps by saying I’ll be fine, you are really saying that you don’t have to think of me in any other way. It works… but who does it work for? People have even argued with me, saying that since I have had treatment for my breast cancer, I am at no greater risk for a recurrence than they are.

Maybe so. But, honestly, you can’t convince me of that.

Once those toxic cells invaded our bodies, we live with the fear it can happen again. And pray that it doesn’t. I have a friend who recently had surgery for kidney cancer. As soon as her surgery was over, she was told by well-meaning people she’ll be fine.

The bottom line is that cancer is a bit of a crap shoot — we play with the odds, statistics, percentages. We try to be “fine,” but as the future is uncertain for all of us, it’d be nice if you tell us how healthy we look, how happy you are to see us and cheer us on.

I’m sure it’s with good intent, but saying, “You’ll be fine” feels dismissive.

Related Videos
a man and a woman in front of a dark blue background
a man and a woman in front of a dark blue background
a man and a woman in separate boxes in front of a dark blue background
Dr. Debu Tripathy discussed the importance of understanding the distinctions between HER2-low and HER2-ultralow breast cancer.
Dr. Debu Tripathy is a professor and chairman of the Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, in Houston, and the editor-in-chief of CURE®.
Dr. Azka Ali is a medical oncologist at the Cleveland Clinic Taussig Cancer Institute, in Ohio.
Dr. Maxwell Lloyd, a Clinical Fellow in Medicine in the Department of Medicine at Beth Israel Deaconess Medical Center in Boston.
Dr. Maxwell Lloyd, a Clinical Fellow in Medicine, in the Department of Medicine, at Beth Israel Deaconess Medical Center in Boston.
Dr. Aditya Bardia is a professor in the Department of Medicine, Division of Hematology/Oncology, director of Translational Research Integration, and a member Signal Transduction and Therapeutics, at University of California, Los Angeles (UCLA) Health Jonsson Comprehensive Cancer Center.
Image of a woman with light shoulder-length hair, wearing rectangular glasses.
Related Content